

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GIANT BIOGENE HOLDING CO., LTD

巨子生物控股有限公司

(An exempted company incorporated in the Cayman Islands with limited liability)

(Stock code: 2367)

PROPOSED ADOPTION OF THE AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION

This announcement is made pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The Board (the “**Board**”) of Directors (the “**Directors**”) of Giant Biogene Holding Co., Ltd (the “**Company**”) proposes certain amendments (the “**Proposed Amendments**”) to the Existing Memorandum and Articles of Association (the “**Existing Memorandum and Articles of Association**”) of the Company in order to (i) update and bring the Existing Memorandum and Articles of Association in line with the relevant amendments to the Listing Rules in respect of the electronic dissemination of corporate communications by listed issuers (effective from 31 December 2023); and (ii) make other consequential and housekeeping amendments to better align with the wordings and requirements under the applicable laws of the Cayman Islands and the Listing Rules. The Board also proposes for the Company to adopt the amended and restated memorandum and articles of association (the “**Amended and Restated Memorandum and Articles of Association**”) of the Company, incorporating and consolidating all Proposed Amendments, in substitution for and to the exclusion of the Existing Memorandum and Articles of Association.

The adoption of the Amended and Restated Memorandum and Articles of Association is subject to the approval by the shareholders of the Company by way of a special resolution at the forthcoming annual general meeting of the Company (the “**AGM**”).

A circular containing, among others, details of the Proposed Amendments brought about by the adoption of the Amended and Restated Memorandum and Articles of Association, together with a notice convening the AGM will be dispatched to the shareholders of the Company in due course.

By Order of the Board
Giant Biogene Holding Co., Ltd
YAN Jianya
Chairman of the Board

Hong Kong, 25 March 2024

As of the date of this announcement, the Board comprises Mr. YAN Jianya, Ms. YE Juan, Ms. FANG Juan, Ms. ZHANG Huijuan and Ms. YAN Yubo as executive Directors, and Mr. HUANG Jin, Mr. SHAN Wenhua and Ms. WONG Sze Wing as independent non-executive Directors.